Time | Topics | Speaker/s |
14:30
-
14:36
|
Comparison of Contrast Sensitivity in Beta-Thalassemia Patients Treated by Desferoxamine or Deferasirox
|
Jafarzadeh pour, Ebrahim MD
|
14:36
-
14:42
|
Experimental Models of Levofloxacin Versus Vancomycin Plus Ceftazidim on Staphylococcus Epidermidis Endophthalmitis
|
Maleki, Alireza MD
|
14:42
-
14:48
|
Intravitreal Diclofenac versus Intravitreal Bevacizumab in Naive Diabetic Macular Edema; A Randomized Double-Masked Clinical Trial
|
Soheilian, Masoud MD
|
14:48
-
14:54
|
Effect of Prophylactic Topical Diclofenac on Cystoid Macular Edema in Diabetic Patients after Phacoemulsification: Randomized Controlled Trial.
|
Entezari, Morteza MD
|
14:54
-
15:00
|
Posterior Vitreous Detachment after Intravitreal Bevacizumab Injection for Retinopathy of Prematurity
|
Hosseini, Seyedeh maryam MD
|
15:00
-
15:06
|
The Effect of Intravitreal Bevacizumab Injection in Patients with Aggressive Posterior Retinopathy of Prematurity: A Prospective Study.
|
Farzinvash, Zahra MD
|
15:06
-
15:12
|
Intra-Silicone Oil Injection of Bevacizumab at The End of Retinal Reattachment Surgery for Severe Proliferative Vitreoretinopathy
|
Ghasemi Falavarjani, Khalil MD
|
15:12
-
15:18
|
Dry Eye after Microincision and Conventional Vitrectomy
|
Ghasemi Falavarjani, Khalil MD
|
15:18
-
15:24
|
Corneal Endothelial Cell Changes Following Pars Plana Vitrectomy and Silicone Oil Injection in Phakic or Pseudophakic Eyes
|
Alivand, Arash MD
|
15:24
-
15:30
|
Intravitreal Autologous Plasmin Prepared by Urokinase for Vitreolysis: A Pilot Study
|
Maleki, Alireza MD
|
15:30
-
15:36
|
The Effects of Intravitreal Bevacizumab on Lateral Geniculate Body (LGB) Electrical Activity in Rat Eyes
|
Kasiri, Ali MD
|
15:36
-
15:42
|
Pseudoretinoblastoma in Iranian Patients
|
Bazvand, Fatemeh MD
|
15:42
-
15:48
|
Clinical Course of Acute Retinal Necrosis after Early/Prophylactic Pars Plana Vitrectomy: Report of Eight Cases
|
Tabatabaei, Ali MD
|
15:48
-
15:54
|
Complications of Retinal Vein Occlusions: Effect of Intravitreal Injection of Bevacizumab.
|
Banaee, Touka MD
|
15:54
-
16:00
|
Questions and Answers
|
|